Current studies evaluating the therapeutic potential of EphA4 antagonists or agonists have been performed to date in either mouse or zebrafish models with mutations in the superoxide dismutase gene, that is representing only one of many genes known to cause ALS. Here, EPHA4 is linked to amyotrophic lateral sclerosis.